PMID- 29505318
OWN - NLM
STAT- MEDLINE
DCOM- 20180528
LR  - 20190222
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 17
IP  - 5
DP  - 2018 May
TI  - A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD.
PG  - 509-517
LID - 10.1080/14740338.2018.1448786 [doi]
AB  - INTRODUCTION: LABA+LAMA and LABA+ICS combinations are key pharmacological 
      approaches to the treatment of COPD. However, both combination types can induce 
      adverse events (AEs). AREAS COVERED: Current literature on LABA+LAMA and LABA+ICS 
      combinations has been reviewed with a specific focus on their safety profile in 
      the treatment of COPD. EXPERT OPINION: Several meta-analyses have compared the 
      pooled safety data from randomized clinical trials (RCTs) of LABA+LAMA 
      combinations with LABA+ICS combinations. LABA+LAMA caused significantly less AEs 
      and SAEs. However, this evidence in real life is less solid because of the lack 
      of appropriate studies. A statistically significant reduction in the risk for 
      pneumonia with LABA+LAMA compared with LABA+ICS has been repeatedly documented by 
      various meta-analyses. The meta-analytic signal indicates that an equal number of 
      patients would die or have cardiac SAEs on LABA+LAMA or LABA+ICS, and in an 
      observational, real-life study the LABA+LAMA combination had similar or lower 
      risk of these events in comparison to LABA+ICS. Nonetheless, since RCTs are 
      conducted under widely varying conditions and, consequently, AE rates of a drug 
      observed in a RCT cannot be directly compared with rates in the RCTs of another 
      drug and may not reflect the rates observed in practice, we need more specific 
      data.
FAU - Matera, Maria Gabriella
AU  - Matera MG
AD  - a Department of Experimental Medicine, Unit of Pharmacology , University of 
      Campania Luigi Vanvitelli , Naples , Italy.
FAU - Calzetta, Luigino
AU  - Calzetta L
AUID- ORCID: 0000-0003-0456-069X
AD  - b Department of Experimental Medicine and Surgery, Unit of Respiratory Medicine , 
      University of Rome Tor Vergata , Rome , Italy.
FAU - Puxeddu, Ermanno
AU  - Puxeddu E
AD  - b Department of Experimental Medicine and Surgery, Unit of Respiratory Medicine , 
      University of Rome Tor Vergata , Rome , Italy.
FAU - Rogliani, Paola
AU  - Rogliani P
AD  - b Department of Experimental Medicine and Surgery, Unit of Respiratory Medicine , 
      University of Rome Tor Vergata , Rome , Italy.
FAU - Cazzola, Mario
AU  - Cazzola M
AUID- ORCID: 0000-0003-4895-9707
AD  - b Department of Experimental Medicine and Surgery, Unit of Respiratory Medicine , 
      University of Rome Tor Vergata , Rome , Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180308
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Muscarinic Antagonists)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenal Cortex Hormones/administration & dosage/*adverse effects
MH  - Adrenergic beta-2 Receptor Agonists/administration & dosage/*adverse effects
MH  - Delayed-Action Preparations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Muscarinic Antagonists/administration & dosage/*adverse effects
MH  - Pulmonary Disease, Chronic Obstructive/drug therapy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Adverse events
OT  - COPD
OT  - ICS
OT  - LABA
OT  - LAMA
OT  - combination therapy
EDAT- 2018/03/06 06:00
MHDA- 2018/05/29 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/05/29 06:00 [medline]
PHST- 2018/03/06 06:00 [entrez]
AID - 10.1080/14740338.2018.1448786 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786. 
      Epub 2018 Mar 8.